TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Combined Cognitive and Gait Training

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Stroke Survivor inclusion/exclusion criteria Inclusion Criteria~* Cognition sufficiently intact to give valid informed consent to participate. \*~* Sufficient endurance to participate in rehabilitation sessions.~* Ability to follow 2 stage commands.~* Medically Stable~* Age \> 21 years.~* Impaired ambulation as follows: inability to flex the knee and ankle in the sagittal plane, in a normal manner so the foot clears the floor; inability to control normal knee angle during single limb weight bearing during stance phase.~* At least 6 months post stroke.~Able-bodied Inclusion criteria~* Criteria to be included is that they should be healthy with no history of a neurological disease or orthopedic impairment.\*\*~* Not Pregnant.~* No Claustrophobia (only for the sub-sample asked to undergo fMRI.)~* No counterindications to MR scanning including, pregnancy, weight inappropriate for height, ferrous objects within the body (only for the sub-sample asked to undergo fMRI.)~Exclusion Criteria:~Exclusion Criteria~* Acute or progressive cardiac, vascular, renal, respiratory, neurological disorders or malignancy.~* Active psychiatric diagnosis or psychological condition, or active drug/alcohol abuse.~* Lower motor neuron damage or radiculopathy.~* Orthopedic impairment. \*\*~* More than one stroke.~* Cerebellar dysfunction.~* Fugl-Meyer lower limb motor sub-score greater than 32.~* No simultaneous gait rehabilitation participation.~* Pregnant.~* Claustrophobia (only for the sub-sample asked to undergo fMRI.)~* Criteria specific to MR scanning, including pregnancy, weight inappropriate for height, ferrous objects within the body (only for the sub-sample asked to undergo fMRI.)

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Gait plus cognitive training (Type: ACTIVE_COMPARATOR): Rehabilitation of walking/gait, combined with rehabilitation of cognitive function
- Gait plus arm training (Type: ACTIVE_COMPARATOR): Rehabilitation of walking/gait, combined with rehabilitation of arm function

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of HIFU-AR on Blood Loss Reduction in Patients With Liver Metastases Requiring Hepatectomy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥ 18 years at the day of consenting to the study.~* Patients with liver metastases requiring a hepatectomy for ≥ 2 segments.~* ECOG PS ≤ 1.~* Adequate bone marrow and liver function at baseline as defined below:~  * Platelet count ≥ 100 x 109/l, and hemoglobin of ≥ 9 g/dl),~ * Total bilirubin ≤ 1.5 x ULN, AST and ALT ≤ 5 x ULN.~* Recovered from prior anti-neoplasic treatment-related toxicity (grade \<2 persistent treatment-related toxicity as per CTCAE v4 are accepted).~* Willingness for follow-up visits.~* Covered by a medical insurance.~* Signed and dated informed consent document indicating that the patient has been informed of all aspects of the trial prior to enrolment.~Exclusion Criteria:~* Patients having previously undergone~  * a major hepatic surgery (i.e. more than 3 liver segments) or~ * biliary major surgery.~* Patient with cirrhosis or sinusoidal obstruction syndrome with portal hypertension.~* Pregnant women (women of childbearing potential are required to have a negative pregnancy test within 72 hours prior to inclusion). A positive urine test must be confirmed by a serum pregnancy test.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Pre-coagulation by HIFU-AR (Type: EXPERIMENTAL): Pre-coagulation of the liver parenchyma with HIFU and standard liver resection
- Standard liver resection (Type: NO_INTERVENTION): Standard liver resection

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Flexible-dose Long-term Extension Study of Lu AF11167 in Patients With Schizophrenia With Prominent Negative Symptoms

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* The patient completed Study 17972A.~* The patient and the patient's caregiver or identified responsible person is able to read and understand the Informed Consent Form.~* The patient has signed the Informed Consent Form specific for Study 17972B.~* The patient can potentially benefit from 24 weeks of treatment with Lu AF11167 according to the investigator's clinical judgment.~Exclusion Criteria:~* The patient has any current primary psychiatric disorder other than schizophrenia diagnosed during study 17972A~* The patient, in the opinion of the investigator, is at significant risk of suicide~Other in- and exclusion criteria may apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Lu AF11167 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Microparticles in Pediatric Inflammatory Disease

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: CROSS_SECTIONAL
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Children with IBD based on endoscopic, histologic, radiologic, or laboratory data~* Ages between 8 and 17 years old~Exclusion Criteria:~* Anyone with a concurrent illness since infection can affect microparticle levels

- Gender: ALL
- Minimum Age: 8 Years
- Maximum Age: 17 Years
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Inpatient COVID-19 Lollipop Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Ability to understand and the willingness to provide verbal informed consent, if 18 years or older. If 4-17 years old, ability to understand and the willingness to provide verbal assent, plus have a parent or legal guardian present who can provide verbal informed consent.~* Willing to comply with all study procedures and be available for the duration of the study.~* Admitted to UW Health University Hospital or UW Health Kids American Family Children's Hospital.~* Individuals at least 4 years of age.~* Verified COVID-19 according to positive NP PCR test criteria.~* Enroll within 47 hours of the diagnostic NP swab; lollipop swab collected within 48 hours of the diagnostic NP swab.~* Either personally able or have a parent or legal guardian able to verbally answer questions in English about clinical symptoms, exposures, and other health and demographic information.~Exclusion Criteria:~* Unable to suck on a swab.~* Previous participation in this study.~* Require translation services for medical care.~* Not suitable for study participation due to other reasons at the discretion of the investigators or their designee.

- Gender: ALL
- Minimum Age: 4 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- COVID-19 Positive Participants (Type: EXPERIMENTAL): Determined by NP PCR test

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Protocol DIVAT-Uro

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients aged over 18 years~* Patients received a kidney transplant or a simultaneous pancreas-kidney transplant~* Patients who read the newsletter and signed the consent form on the computerization of data~Exclusion Criteria:~* Patients aged under 18 years~* Patients who did not sign the consent form

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Capture data (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Safety Study of Cervical Sympathetic Block for Cerebral Vasospasm Following Aneurysmal Subarachnoid Hemorrhage

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. High grade spontaneous SAH (Fisher Grade III and IV)~2. Secured aneurysm (clipped/coiled)~3. Evidence of severe vasospasm - MCA mean flow velocity \>200 cm/sec and Lindegaard ratio \>6 OR Symptomatic vasospasm with either angiographic evidence (no angioplasty), or at least moderate severity according to TCD criteria (MCA mean flow velocity \>150 cm/sec and Lindegaard ratio \>3, or ACA vasospasm)~4. Age ≥18~Exclusion Criteria:~1. Allergy to local anesthetic or contrast~2. Coagulation disorders with PT \<70%, or INR \>1.4, or PTT \>1.5 times control and/or platelets \<70,000x106/L~3. Use of enoxaparin within 12 hours~4. Use of clopidogrel within 7 days~5. Use of coumadin within 5 days~6. Use of ticlopidine within 14 days~7. Use of intravenous thrombolytics within 10 days~8. Any use of hirudin derivatives during ICU stay

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Block (Type: EXPERIMENTAL): None
- Standard Care (Type: NO_INTERVENTION): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: High Flow Nasal Oxygen for Children With Cystic Fibrosis Presenting With Respiratory Failure - a Randomized Controlled Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Established diagnosis of cystic fibrosis~* Age between 6 and 17 years~* Ability to perform lung function testing~* Hospital admission due to acute pulmonary exacerbation in the last 12h~* Regular use of Pulmozyme~* Need for high FiO2 defined as more than 2 liters per minute in the nasal cannula or need of a Venturi mask~Exclusion Criteria:~* Recent admission (less than 30 days)~* Recent or current atelectasis (less than 3 months)~* Hemoptysis or pneumothorax~* Need for a bronchoscopy during admission~* Need for non-invasive ventilation for more than 2 hours/day

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Hi-flow nasal cannula (Type: EXPERIMENTAL): This group will receive supplemental oxygen by nasal cannula using the Optiflow system, with high flows of 100% humidified oxygen
- Venturi mask (Type: ACTIVE_COMPARATOR): This group will receive supplemental oxygen by the current standard in our Institution: Venturi masks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Oral Therapeutic Education in Stimulated Parkinsonian Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with idiopathic Parkinson's disease for whom deep brain stimulation surgery (indifferent target) has been indicated for their Parkinson's disease~* affiliated to a system of social security;~* having at least 10 natural teeth (treated or not)~* having received oral and written information on the protocol and having signed a consent to participate in this research.~Exclusion Criteria:~* pregnant or lactating women;~* Persons of legal age subject to legal protection (safeguard of justice, guardianship, tutorship), persons deprived of their liberty;~* Patients who do not speak French (both written and spoken);~* Patients whose oral status is considered incompatible by the dental surgeon investigator with entry into the study (history of major maxillofacial surgery, presence of drugs that may cause gingival hypertrophy 2 or gingival bleeding 3).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Classical care pathway (Type: NO_INTERVENTION): Patients are following classical care pathway. Before brain surgery patients will be included after oral, medical and life quality evaluation.~After randomization in the control group, patients will be evaluated at 6 and 12months after surgery, during classical follow up visits.
- Oral education (Type: EXPERIMENTAL): Patients are following classical care pathway but combined at each visit with an oral education Before brain surgery patients will be included after oral, medical and life quality evaluation.~After randomization in the experimental group, patients will be evaluated at 6 and 12 months after surgery, during classical follow up visits. At each timepoint an oral education will be realized in parallel.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: An Open-label, Randomized Phase II Study to Evaluate the Efficacy of AUY922 vs Pemetrexed or Docetaxel in NSCLC Patients With EGFR Mutations

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients with histologically or cytologically documented, locally advanced (stage IIIB who are not amenable to combined modality treatment) or recurrent or metastatic (Stage IV) non-small cell lung cancer.~2. Patients must have EGFR gene mutation in their tumors. This can be source - documented by one of the following:~   • Provide a pathology report that indicates the patient's tumor had EGFR activating mutation in the past.~   Or:~   • Perform testing (local or central) in an archival tumor or a fresh baseline biopsy tumor tissue to show the presence of EGFR activating mutation.~3. Patients must have documented clinical benefit (CR, PR, or patients with SD for 6 months or greater) on prior EGFR TKI (e.g. erlotinib or gefitinib) followed by documented progression according to RECIST.~4. Patients must have received prior platinum containing treatment.~5. WHO performance status of 0-1~Exclusion Criteria:~1. Patients who have received more than two prior lines of antineoplastic therapy for advanced disease. Chemotherapy administered as neoadjuvant or adjuvant treatment more than six months prior to study enrollment is not considered a prior line of therapy for purposes of this study.~2. Evidence of spinal cord compression or current evidence of CNS metastases. Screening CT/MRI of the brain is mandatory. Note: Patients who have been treated for CNS metastases by radiation or gamma knife surgery, who been stable for at least 2 months and have discontinued high dose corticosteroids will be eligible for protocol participation~3. Prior treatment with an HSP90 inhibitor

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- AUY922 arm (Type: EXPERIMENTAL): Participants were assigned to one of two treatment arms in a ratio of 1:1. This was the investigational drug arm.~AUY922 was to be administered weekly.
- chemotherapy arm (Type: ACTIVE_COMPARATOR): Participants were assigned to one of two treatment arms in a ratio of 1:1. This was the control arm drug arm.~Pemetrexed or docetaxel was to be was to be given once every three weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Clinical Trial of Growth Hormone in MPS I, II, and VI

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* A parent or legally authorized representative must provide written informed consent and comply with study assessments for the full duration of the study.~* Chronologic age ≥ 5 years and bone age ≤12 years~* Diagnosis of MPS I, II, or VI~* Height ≤ -2 SDS for age and gender~* Ability to travel to study center for evaluations.~* Ability of the participant to cooperate with study procedures, to notify a guardian of symptoms, and provide assent for participation in the study.~Exclusion Criteria:~* History of treatment with hGH~* Untreated pituitary deficiency~* Pregnancy (positive urine pregnancy test) prior to enrollment in the study~* Participation in another simultaneous medical intervention trial~* Patients with closed epiphysis~* Active neoplasm~* Orthopedic procedure of the femur within the last 6 months.~* Known or suspected allergy to trial product or related products.~* Structural lesion on brain MRI resulting in brain compression~* Any other social or medical condition that the investigator believes would pose a significant hazard to the subject if the investigational therapy were initiated or be detrimental to the study.~* Obstructive sleep apnea without BiPAP or tonsillectomy/adenoidectomy treatment.~* CNS shunt.~* Abnormal cardiac function based on echocardiogram within 6 months prior to enrollment :~* Ejection fraction less than 50%~* Left ventricular chamber size greater than or less than 2 standard deviations of normal for body surface area~* Left ventricular wall thickness greater than or less than 2 standard deviations of normal for body surface area~* More than mild to moderate aortic insufficiency with abdominal aortic run-off~* More than mild to moderate mitral insufficiency with pulmonary hypertension~* Abnormal pulmonary function based on pulmonary function tests within 6 months prior to enrollment:~* abnormal FVC \< 80% of predicted for age, gender, and height~* abnormal FEV1 \< 80% predicted for age, gender, and height~* abnormal FEV1/FVC~* abnormal oxygen saturation

- Gender: ALL
- Minimum Age: 5 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Growth hormone treatmen (Type: EXPERIMENTAL): Growth hormone treatment arm. Somatropin (DNA origin)
- No growth hormone treatment in year 1 (Type: NO_INTERVENTION): No growth hormone treatment in year 1; option for treatment in year 2 open-label period.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Fetal Scalp Stimulation Versus Fetal Blood Sampling in Labour

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Nulliparous women~* Singleton pregnancy~* Cephalic presentation~* Gestational age 37+0 weeks or greater~* Abnormal CTG that requires second-line testing (FBS or dFSS)~Exclusion Criteria:~* Contraindication to FBS~* Limited understanding of English~* At the discretion of the responsible obstetrician in cases where there is urgency

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Fetal Blood Sampling (FBS) (Type: ACTIVE_COMPARATOR): Fetal capillary blood samples will be collected in heparinised tubes and analysed in the delivery suite using the locally available gas analyser. The result of the first technically reliable sample, or the lowest reliable sample if multiple samples are tested, will be interpreted and acted upon according to the protocol, taking account of the clinical circumstances and the stage of labour:~pH ≥7.25 normal, continue and if indicated repeat in 60 minutes; pH 7.21-7.24 borderline, repeat in 30 minutes; pH ≤ 7.20 abnormal, deliver.
- digital Fetal Scalp Stimulation (dFSS) (Type: ACTIVE_COMPARATOR): The examiner will stimulate the fetal scalp digitally with the index and middle finger over a period of 30-60 seconds.The CTG will be observed over a 5-10 minutes interval after the dFSS and if a fetal heart rate acceleration (\>15 bpm for 15 seconds) is observed the test will be considered normal. If there is an episode of normal variability (5-25 bpm) but there is no clear acceleration, the test will be considered borderline. If there is no FHR acceleration and no episode of normal variability with ongoing abnormal features, the test should be interpreted as abnormal in the same way as an abnormal FBS result.~FHR acceleration normal, if indicated repeat in 60 min; Uncertain acceleration/ normal variability borderline, repeat in 30 minutes; No Acceleration/ongoing abnormal features abnormal, deliver.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy